DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
4.520
-0.020 (-0.44%)
Jan 21, 2025, 4:00 PM EST - Market closed
DBV Technologies Revenue
DBV Technologies had revenue of $1.07M in the quarter ending September 30, 2024, a decrease of -54.81%. This brings the company's revenue in the last twelve months to $12.52M, up 125.54% year-over-year. In the year 2023, DBV Technologies had annual revenue of $15.73M with 224.69% growth.
Revenue (ttm)
$12.52M
Revenue Growth
+125.54%
P/S Ratio
n/a
Revenue / Employee
$119,190
Employees
105
Market Cap
96.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | 14.71M | 3.52M | 31.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
DBVT News
- 8 days ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire
- 5 weeks ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 5 weeks ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire
- 2 months ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire
- 2 months ago - DBV Technologies Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewsWire
- 3 months ago - DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - GlobeNewsWire
- 4 months ago - DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial - GlobeNewsWire